Oncology Data Advisor

Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient? In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on: 🔹The Nuances of Modern Selection: Balancing comorbidities and logistical hurdles. 🔹Managing Induction Burden: Proactive strategies for steroid side effects and neuropathy. 🔹Pragmatic Dosing: Finding the most sustainable, real-world dose for frail or older patients. 📅 Save Your Spot for the Live Event! Get case-based guidance from Dr. Rahul Banerjee, Dr. Ashley Chen, and Dr. Beth Faiman. Session 1: July 8 at 6:00 pm ET: bit.ly/3SitVaC Session 2: July 28 at 7:00 pm ET: bit.ly/4oIAcZo

Neuroendocrine tumor (NET) care is changing fast—and the pace of innovation is only accelerating. In this episode, Aman Chauhan, MD, Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF), breaks down the latest advances that are reshaping how clinicians diagnose and treat NETs. Dr. Chauhan, who recently chaired i3 Health’s CME activity Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, returns to highlight what’s new and what matters most for practice. From evolving epidemiologic insights to emerging targeted therapies and next‑generation immunotherapies, he explains how these developments are expanding options for patients and refining real‑world decision making. Whether you’re a clinician treating NETs, a trainee looking to stay current, or a listener interested in where cancer care is headed next, this conversation offers a concise, high‑yield tour of the NET landscape—and where it’s going next. Click the link to view the full activity and claim your free CME credit: https://bit.ly/41Qo65Y Click here to download/view the infographic: https://bit.ly/4bbSUmL

Read the full article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-financial-toxicity In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, and Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, explore how financial and geographic toxicities in oncology are, in reality, clinical toxicities. If a patient can’t afford to fill the prescription, is it really a treatment option? They discuss what financial toxicity truly means—far beyond drug prices—covering travel, parking, time off work, and the hidden costs of tests and therapies. Dr. Hadfield shares real-world examples of patients turning down innovative treatments and clinical trials because they can’t afford the logistical burden, and explains how geography and income create a two-tiered system of cancer care. The conversation examines how financial and geographic barriers distort shared decision making, limit participation in clinical trials, and skew our understanding of real-world efficacy. They also highlight the role of institutions, policymakers, and pharma in improving access, and why oncologists must reconsider ordering patterns, testing habits, and how they counsel patients about the full “cost” of care. Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month’s topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity. Click the link to complete module 2 and claim your free credit: bit.ly/44yO9RB

Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available. You can catch the live session on either of these dates: Wednesday, January 8 at 5:00 pm ET: https://bit.ly/4iZxnA0 Monday, January 26 at 5:00 pm ET: https://bit.ly/4qALw9J

Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 1 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies" Don't forget to claim your credit after the episode! Click on the link to claim your credit for module 1: bit.ly/3Y3ivHM Click here to continue listening to Module 2 of this podcast series: bit.ly/43VoFNP

Transform your approach to CLL care with insights from clinical pharmacy expert, "Kelsey Marciano, PharmD, BCOP,UCHealth. This podcast unpacks the latest strategies for treatment selection and toxicity management—empowering oncology pharmacists to lead confidently, maximize patient outcomes, and deliver next-level care in the evolving era of oral targeted therapies. 🎧 Listen now and click the link to claim your CE credit! Claim your credit here: bit.ly/4pGrLO5 🔗 Learn more and access continuing education activities: i3health.com 📲 Stay connected with i3 Health: Twitter/X: https://bit.ly/3ITDaJV Facebook: https://bit.ly/46wmwJo YouTube: https://bit.ly/46PXLXx 🎧 Subscribe to the Oncology Data Advisor Podcast on your favorite streaming platform so you never miss the latest expert discussions!